SCHEMBL2221025

SCHEMBL2221025

Cc1cccc(Oc2ncc3nc(-c4cc(C)c(OCC(=O)O)c(C)c4)oc3n2)c1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 1/20 0.83
CETP P11597 3/20 0.41
MAPT P10636 5/20 0.38
THRB P10828 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
HTT P42858 1/20 0.38
PPARG P37231 1/20 0.36
PPARA Q07869 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
GLA P06280 1/20 0.36
TP53 P04637 2/20 0.35
RXFP1 Q9HBX9 1/20 0.35
FFAR1 O14842 1/20 0.35
POLB P06746 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2223368 0.92 S1PR1 (0.83) S1PR1CETPMAPTMEN1KMT2A
SCHEMBL14797011 0.92 S1PR1 (0.82) S1PR1CETPMAPTMEN1KMT2A
SCHEMBL2224170 0.91 S1PR1 (1.00) S1PR1CETPMEN1KMT2APPARG
SCHEMBL2222592 0.91 S1PR1 (0.81) S1PR1CETPPPARGPPARAFFAR1
SCHEMBL2223316 0.90 S1PR1 (0.75) S1PR1CETPMAPTTHRBKMT2A
SCHEMBL14797145 0.89 S1PR1 (0.77) S1PR1THRBMEN1KMT2APPARG
SCHEMBL14797208 0.89 S1PR1 (0.77) S1PR1CETPMAPTTHRBPPARG
SCHEMBL14797047 0.89 S1PR1 (0.77) S1PR1CETPPPARGPPARAPTPN1
SCHEMBL14796988 0.88 S1PR1 (0.70) S1PR1CETPMAPTPPARGPPARA
SCHEMBL14797340 0.86 S1PR1 (0.73) S1PR1CETPPPARGPPARAFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846692-B2 Carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring SANOFI (FR) 2014-09-30 US disclosed
EP-2523962-B1 CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING SANOFI SA (FR) 2013-11-27 EP disclosed
US-20130079358-A1 CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING SANOFI (FR) 2013-03-28 US disclosed
EP-2523962-A1 CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING SANOFI (FR) 2012-11-21 EP disclosed
WO-2011086079-A1 CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING SANOFI-AVENTIS (FR) 2011-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079358-A1 CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING OXGR1, EDNRA, EDF1 S1PR1 129/4885CETP 3150/4885MAPT 4394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.